HCW Biologics Inc HCWB
π Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-07-20 |
| Shares Out. | 1,600,000 |
| Website | hcwbiologics.com/ β |
| Phone | 18009279800 |
| Employees | 35 |
| Revenue | $6.5M |
| Gross Profit | $6.5M |
| Net Income | $3.5M |
| Total Assets | $27.3M |
| Total Liabilities | $21.6M |
| Equity | $5.8M |
About HCW Biologics Inc
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
HCW Biologics Inc is a publicly traded company under the ticker symbol HCWB on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
π Analyst Ratings
7 analysts (2026-07-01)

